Global Neuroendocrine Tumor Drug Market Research Report 2024

Report ID: 1977487 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Neuroendocrine Tumor Drug Market Overview
    1.1 Product Overview and Scope of Neuroendocrine Tumor Drug
    1.2 Neuroendocrine Tumor Drug Segment by Type
        1.2.1 Global Neuroendocrine Tumor Drug Market Value Comparison by Type (2023-2029)
        1.2.2 mTOR Protein Inhibitors
        1.2.3 Tyrosine Kinase 3 Inhibitors
        1.2.4 Somatostatin Receptor Antagonists
        1.2.5 Growth Hormone Releasing Factor Antagonists
        1.2.6 Somatostatin Receptor Agonists
        1.2.7 Others
    1.3 Neuroendocrine Tumor Drug Segment by Application
        1.3.1 Global Neuroendocrine Tumor Drug Market Value by Application: (2023-2029)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Neuroendocrine Tumor Drug Market Size Estimates and Forecasts
        1.4.1 Global Neuroendocrine Tumor Drug Revenue 2018-2029
        1.4.2 Global Neuroendocrine Tumor Drug Sales 2018-2029
        1.4.3 Global Neuroendocrine Tumor Drug Market Average Price (2018-2029)
    1.5 Assumptions and Limitations
2 Neuroendocrine Tumor Drug Market Competition by Manufacturers
    2.1 Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2018-2023)
    2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2018-2023)
    2.3 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2018-2023)
    2.4 Global Neuroendocrine Tumor Drug Industry Ranking 2021 VS 2022 VS 2023
    2.5 Global Key Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
    2.6 Global Key Manufacturers of Neuroendocrine Tumor Drug, Product Type & Application
    2.7 Neuroendocrine Tumor Drug Market Competitive Situation and Trends
        2.7.1 Neuroendocrine Tumor Drug Market Concentration Rate
        2.7.2 The Global Top 5 and Top 10 Largest Neuroendocrine Tumor Drug Players Market Share by Revenue
        2.7.3 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuroendocrine Tumor Drug Retrospective Market Scenario by Region
    3.1 Global Neuroendocrine Tumor Drug Market Size by Region: 2018 Versus 2022 Versus 2029
    3.2 Global Neuroendocrine Tumor Drug Global Neuroendocrine Tumor Drug Sales by Region: 2018-2029
        3.2.1 Global Neuroendocrine Tumor Drug Sales by Region: 2018-2023
        3.2.2 Global Neuroendocrine Tumor Drug Sales by Region: 2024-2029
    3.3 Global Neuroendocrine Tumor Drug Global Neuroendocrine Tumor Drug Revenue by Region: 2018-2029
        3.3.1 Global Neuroendocrine Tumor Drug Revenue by Region: 2018-2023
        3.3.2 Global Neuroendocrine Tumor Drug Revenue by Region: 2024-2029
    3.4 North America Neuroendocrine Tumor Drug Market Facts & Figures by Country
        3.4.1 North America Neuroendocrine Tumor Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.4.2 North America Neuroendocrine Tumor Drug Sales by Country (2018-2029)
        3.4.3 North America Neuroendocrine Tumor Drug Revenue by Country (2018-2029)
        3.4.4 U.S.
        3.4.5 Canada
    3.5 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Country
        3.5.1 Europe Neuroendocrine Tumor Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.5.2 Europe Neuroendocrine Tumor Drug Sales by Country (2018-2029)
        3.5.3 Europe Neuroendocrine Tumor Drug Revenue by Country (2018-2029)
        3.5.4 Germany
        3.5.5 France
        3.5.6 U.K.
        3.5.7 Italy
        3.5.8 Russia
    3.6 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Country
        3.6.1 Asia Pacific Neuroendocrine Tumor Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.6.2 Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2018-2029)
        3.6.3 Asia Pacific Neuroendocrine Tumor Drug Revenue by Country (2018-2029)
        3.6.4 China
        3.6.5 Japan
        3.6.6 South Korea
        3.6.7 India
        3.6.8 Australia
        3.6.9 Taiwan
        3.6.10 Indonesia
        3.6.11 Thailand
        3.6.12 Malaysia
        3.6.13 Philippines
    3.7 Latin America Neuroendocrine Tumor Drug Market Facts & Figures by Country
        3.7.1 Latin America Neuroendocrine Tumor Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.7.2 Latin America Neuroendocrine Tumor Drug Sales by Country (2018-2029)
        3.7.3 Latin America Neuroendocrine Tumor Drug Revenue by Country (2018-2029)
        3.7.4 Mexico
        3.7.5 Brazil
        3.7.6 Argentina
    3.8 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Country
        3.8.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.8.2 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2018-2029)
        3.8.3 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2018-2029)
        3.8.4 Turkey
        3.8.5 Saudi Arabia
        3.8.6 UAE
4 Segment by Type
    4.1 Global Neuroendocrine Tumor Drug Sales by Type (2018-2029)
        4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2018-2023)
        4.1.2 Global Neuroendocrine Tumor Drug Sales by Type (2024-2029)
        4.1.3 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2018-2029)
    4.2 Global Neuroendocrine Tumor Drug Revenue by Type (2018-2029)
        4.2.1 Global Neuroendocrine Tumor Drug Revenue by Type (2018-2023)
        4.2.2 Global Neuroendocrine Tumor Drug Revenue by Type (2024-2029)
        4.2.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2018-2029)
    4.3 Global Neuroendocrine Tumor Drug Price by Type (2018-2029)
5 Segment by Application
    5.1 Global Neuroendocrine Tumor Drug Sales by Application (2018-2029)
        5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2018-2023)
        5.1.2 Global Neuroendocrine Tumor Drug Sales by Application (2024-2029)
        5.1.3 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2018-2029)
    5.2 Global Neuroendocrine Tumor Drug Revenue by Application (2018-2029)
        5.2.1 Global Neuroendocrine Tumor Drug Revenue by Application (2018-2023)
        5.2.2 Global Neuroendocrine Tumor Drug Revenue by Application (2024-2029)
        5.2.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2018-2029)
    5.3 Global Neuroendocrine Tumor Drug Price by Application (2018-2029)
6 Key Companies Profiled
    6.1 Eisai
        6.1.1 Eisai Corporation Information
        6.1.2 Eisai Description and Business Overview
        6.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.1.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
        6.1.5 Eisai Recent Developments/Updates
    6.2 Exelixis, Inc.
        6.2.1 Exelixis, Inc. Corporation Information
        6.2.2 Exelixis, Inc. Description and Business Overview
        6.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.2.5 Exelixis, Inc. Recent Developments/Updates
    6.3 Foresee Pharmaceuticals, LLC
        6.3.1 Foresee Pharmaceuticals, LLC Corporation Information
        6.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
        6.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
        6.3.5 Foresee Pharmaceuticals, LLC Recent Developments/Updates
    6.4 Hutchison MediPharma Limited
        6.4.1 Hutchison MediPharma Limited Corporation Information
        6.4.2 Hutchison MediPharma Limited Description and Business Overview
        6.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
        6.4.5 Hutchison MediPharma Limited Recent Developments/Updates
    6.5 Intezyne, Inc
        6.5.1 Intezyne, Inc Corporation Information
        6.5.2 Intezyne, Inc Description and Business Overview
        6.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
        6.5.5 Intezyne, Inc Recent Developments/Updates
    6.6 INVENT Pharmaceuticals, Inc.
        6.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
        6.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
        6.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.6.5 INVENT Pharmaceuticals, Inc. Recent Developments/Updates
    6.7 Ipsen S.A.
        6.6.1 Ipsen S.A. Corporation Information
        6.6.2 Ipsen S.A. Description and Business Overview
        6.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
        6.7.5 Ipsen S.A. Recent Developments/Updates
    6.8 Jiangsu Hengrui Medicine Co., Ltd.
        6.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
        6.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
        6.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
        6.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments/Updates
    6.9 Karyopharm Therapeutics, Inc.
        6.9.1 Karyopharm Therapeutics, Inc. Corporation Information
        6.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
        6.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.9.5 Karyopharm Therapeutics, Inc. Recent Developments/Updates
    6.10 Lexicon Pharmaceuticals, Inc.
        6.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
        6.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
        6.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.10.5 Lexicon Pharmaceuticals, Inc. Recent Developments/Updates
    6.11 Midatech Pharma Plc .
        6.11.1 Midatech Pharma Plc . Corporation Information
        6.11.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Description and Business Overview
        6.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.11.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
        6.11.5 Midatech Pharma Plc . Recent Developments/Updates
    6.12 Millennium Pharmaceuticals, Inc.
        6.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
        6.12.2 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Description and Business Overview
        6.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.12.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.12.5 Millennium Pharmaceuticals, Inc. Recent Developments/Updates
    6.13 MolMed S.p.A.
        6.13.1 MolMed S.p.A. Corporation Information
        6.13.2 MolMed S.p.A. Neuroendocrine Tumor Drug Description and Business Overview
        6.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.13.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
        6.13.5 MolMed S.p.A. Recent Developments/Updates
    6.14 Northwest Biotherapeutics, Inc.
        6.14.1 Northwest Biotherapeutics, Inc. Corporation Information
        6.14.2 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Description and Business Overview
        6.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.14.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.14.5 Northwest Biotherapeutics, Inc. Recent Developments/Updates
    6.15 Novartis AG
        6.15.1 Novartis AG Corporation Information
        6.15.2 Novartis AG Neuroendocrine Tumor Drug Description and Business Overview
        6.15.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.15.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
        6.15.5 Novartis AG Recent Developments/Updates
    6.16 OctreoPharm Sciences GmbH
        6.16.1 OctreoPharm Sciences GmbH Corporation Information
        6.16.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Description and Business Overview
        6.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.16.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
        6.16.5 OctreoPharm Sciences GmbH Recent Developments/Updates
    6.17 OXiGENE, Inc.
        6.17.1 OXiGENE, Inc. Corporation Information
        6.17.2 OXiGENE, Inc. Neuroendocrine Tumor Drug Description and Business Overview
        6.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2023)
        6.17.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
        6.17.5 OXiGENE, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
    7.1 Neuroendocrine Tumor Drug Industry Chain Analysis
    7.2 Neuroendocrine Tumor Drug Key Raw Materials
       7.2.1 Key Raw Materials
       7.2.2 Raw Materials Key Suppliers
    7.3 Neuroendocrine Tumor Drug Production Mode & Process
    7.4 Neuroendocrine Tumor Drug Sales and Marketing
        7.4.1 Neuroendocrine Tumor Drug Sales Channels
        7.4.2 Neuroendocrine Tumor Drug Distributors
    7.5 Neuroendocrine Tumor Drug Customers
8 Neuroendocrine Tumor Drug Market Dynamics
    8.1 Neuroendocrine Tumor Drug Industry Trends
    8.2 Neuroendocrine Tumor Drug Market Drivers
    8.3 Neuroendocrine Tumor Drug Market Challenges
    8.4 Neuroendocrine Tumor Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
    10.1 Methodology/Research Approach
        10.1.1 Research Programs/Design
        10.1.2 Market Size Estimation
        10.1.3 Market Breakdown and Data Triangulation
    10.2 Data Source
        10.2.1 Secondary Sources
        10.2.2 Primary Sources
    10.3 Author List
    10.4 Disclaimer

List of Tables
    Table 1. Global Neuroendocrine Tumor Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Neuroendocrine Tumor Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Neuroendocrine Tumor Drug Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Neuroendocrine Tumor Drug Sales (K Pcs) of Key Manufacturers (2018-2023)
    Table 5. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Neuroendocrine Tumor Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Neuroendocrine Tumor Drug, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Neuroendocrine Tumor Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Neuroendocrine Tumor Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Tumor Drug as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Neuroendocrine Tumor Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Neuroendocrine Tumor Drug Sales by Region (2018-2023) & (K Pcs)
    Table 18. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2018-2023)
    Table 19. Global Neuroendocrine Tumor Drug Sales by Region (2024-2029) & (K Pcs)
    Table 20. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2024-2029)
    Table 21. Global Neuroendocrine Tumor Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2018-2023)
    Table 23. Global Neuroendocrine Tumor Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2024-2029)
    Table 25. North America Neuroendocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Neuroendocrine Tumor Drug Sales by Country (2018-2023) & (K Pcs)
    Table 27. North America Neuroendocrine Tumor Drug Sales by Country (2024-2029) & (K Pcs)
    Table 28. North America Neuroendocrine Tumor Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Neuroendocrine Tumor Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Neuroendocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Neuroendocrine Tumor Drug Sales by Country (2018-2023) & (K Pcs)
    Table 32. Europe Neuroendocrine Tumor Drug Sales by Country (2024-2029) & (K Pcs)
    Table 33. Europe Neuroendocrine Tumor Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Neuroendocrine Tumor Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2018-2023) & (K Pcs)
    Table 37. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2024-2029) & (K Pcs)
    Table 38. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Neuroendocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Neuroendocrine Tumor Drug Sales by Country (2018-2023) & (K Pcs)
    Table 42. Latin America Neuroendocrine Tumor Drug Sales by Country (2024-2029) & (K Pcs)
    Table 43. Latin America Neuroendocrine Tumor Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Neuroendocrine Tumor Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2018-2023) & (K Pcs)
    Table 47. Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2024-2029) & (K Pcs)
    Table 48. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2018-2023)
    Table 51. Global Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2024-2029)
    Table 52. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2018-2023)
    Table 53. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2024-2029)
    Table 54. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2018-2023)
    Table 57. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2024-2029)
    Table 58. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2018-2023)
    Table 59. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2024-2029)
    Table 60. Global Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2018-2023)
    Table 61. Global Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2024-2029)
    Table 62. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2018-2023)
    Table 63. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2024-2029)
    Table 64. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2018-2023)
    Table 67. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2024-2029)
    Table 68. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Application (2018-2023)
    Table 69. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Application (2024-2029)
    Table 70. Eisai Corporation Information
    Table 71. Eisai Description and Business Overview
    Table 72. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 73. Eisai Neuroendocrine Tumor Drug Product
    Table 74. Eisai Recent Developments/Updates
    Table 75. Exelixis, Inc. Corporation Information
    Table 76. Exelixis, Inc. Description and Business Overview
    Table 77. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 78. Exelixis, Inc. Neuroendocrine Tumor Drug Product
    Table 79. Exelixis, Inc. Recent Developments/Updates
    Table 80. Foresee Pharmaceuticals, LLC Corporation Information
    Table 81. Foresee Pharmaceuticals, LLC Description and Business Overview
    Table 82. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 83. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product
    Table 84. Foresee Pharmaceuticals, LLC Recent Developments/Updates
    Table 85. Hutchison MediPharma Limited Corporation Information
    Table 86. Hutchison MediPharma Limited Description and Business Overview
    Table 87. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 88. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product
    Table 89. Hutchison MediPharma Limited Recent Developments/Updates
    Table 90. Intezyne, Inc Corporation Information
    Table 91. Intezyne, Inc Description and Business Overview
    Table 92. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 93. Intezyne, Inc Neuroendocrine Tumor Drug Product
    Table 94. Intezyne, Inc Recent Developments/Updates
    Table 95. INVENT Pharmaceuticals, Inc. Corporation Information
    Table 96. INVENT Pharmaceuticals, Inc. Description and Business Overview
    Table 97. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 98. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product
    Table 99. INVENT Pharmaceuticals, Inc. Recent Developments/Updates
    Table 100. Ipsen S.A. Corporation Information
    Table 101. Ipsen S.A. Description and Business Overview
    Table 102. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 103. Ipsen S.A. Neuroendocrine Tumor Drug Product
    Table 104. Ipsen S.A. Recent Developments/Updates
    Table 105. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
    Table 106. Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
    Table 107. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 108. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product
    Table 109. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments/Updates
    Table 110. Karyopharm Therapeutics, Inc. Corporation Information
    Table 111. Karyopharm Therapeutics, Inc. Description and Business Overview
    Table 112. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 113. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product
    Table 114. Karyopharm Therapeutics, Inc. Recent Developments/Updates
    Table 115. Lexicon Pharmaceuticals, Inc. Corporation Information
    Table 116. Lexicon Pharmaceuticals, Inc. Description and Business Overview
    Table 117. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 118. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product
    Table 119. Lexicon Pharmaceuticals, Inc. Recent Developments/Updates
    Table 120. Midatech Pharma Plc . Corporation Information
    Table 121. Midatech Pharma Plc . Description and Business Overview
    Table 122. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 123. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product
    Table 124. Midatech Pharma Plc . Recent Developments/Updates
    Table 125. Millennium Pharmaceuticals, Inc. Corporation Information
    Table 126. Millennium Pharmaceuticals, Inc. Description and Business Overview
    Table 127. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 128. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product
    Table 129. Millennium Pharmaceuticals, Inc. Recent Developments/Updates
    Table 130. MolMed S.p.A. Corporation Information
    Table 131. MolMed S.p.A. Description and Business Overview
    Table 132. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 133. MolMed S.p.A. Neuroendocrine Tumor Drug Product
    Table 134. MolMed S.p.A. Recent Developments/Updates
    Table 135. Northwest Biotherapeutics, Inc. Corporation Information
    Table 136. Northwest Biotherapeutics, Inc. Description and Business Overview
    Table 137. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 138. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product
    Table 139. Northwest Biotherapeutics, Inc. Recent Developments/Updates
    Table 140. Novartis AG Corporation Information
    Table 141. Novartis AG Description and Business Overview
    Table 142. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 143. Novartis AG Neuroendocrine Tumor Drug Product
    Table 144. Novartis AG Recent Developments/Updates
    Table 145. OctreoPharm Sciences GmbH Corporation Information
    Table 146. OctreoPharm Sciences GmbH Description and Business Overview
    Table 147. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 148. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product
    Table 149. OctreoPharm Sciences GmbH Recent Developments/Updates
    Table 150. OXiGENE, Inc. Corporation Information
    Table 151. OXiGENE, Inc. Description and Business Overview
    Table 152. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 153. OXiGENE, Inc. Neuroendocrine Tumor Drug Product
    Table 154. OXiGENE, Inc. Recent Developments/Updates
    Table 155. Key Raw Materials Lists
    Table 156. Raw Materials Key Suppliers Lists
    Table 157. Neuroendocrine Tumor Drug Distributors List
    Table 158. Neuroendocrine Tumor Drug Customers List
    Table 159. Neuroendocrine Tumor Drug Market Trends
    Table 160. Neuroendocrine Tumor Drug Market Drivers
    Table 161. Neuroendocrine Tumor Drug Market Challenges
    Table 162. Neuroendocrine Tumor Drug Market Restraints
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Neuroendocrine Tumor Drug
    Figure 2. Global Neuroendocrine Tumor Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Neuroendocrine Tumor Drug Market Share by Type in 2022 & 2029
    Figure 4. mTOR Protein Inhibitors Product Picture
    Figure 5. Tyrosine Kinase 3 Inhibitors Product Picture
    Figure 6. Somatostatin Receptor Antagonists Product Picture
    Figure 7. Growth Hormone Releasing Factor Antagonists Product Picture
    Figure 8. Somatostatin Receptor Agonists Product Picture
    Figure 9. Others Product Picture
    Figure 10. Global Neuroendocrine Tumor Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global Neuroendocrine Tumor Drug Market Share by Application in 2022 & 2029
    Figure 12. Hospital
    Figure 13. Clinic
    Figure 14. Others
    Figure 15. Global Neuroendocrine Tumor Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Neuroendocrine Tumor Drug Market Size (2018-2029) & (US$ Million)
    Figure 17. Global Neuroendocrine Tumor Drug Sales (2018-2029) & (K Pcs)
    Figure 18. Global Neuroendocrine Tumor Drug Average Price (USD/Pcs) & (2018-2029)
    Figure 19. Neuroendocrine Tumor Drug Report Years Considered
    Figure 20. Neuroendocrine Tumor Drug Sales Share by Manufacturers in 2022
    Figure 21. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers in 2022
    Figure 22. The Global 5 and 10 Largest Neuroendocrine Tumor Drug Players: Market Share by Revenue in 2022
    Figure 23. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 24. Global Neuroendocrine Tumor Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 25. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2018-2029)
    Figure 26. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2018-2029)
    Figure 27. U.S. Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 28. Canada Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2018-2029)
    Figure 30. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2018-2029)
    Figure 31. Germany Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. France Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. U.K. Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Italy Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Russia Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2018-2029)
    Figure 37. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2018-2029)
    Figure 38. China Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Japan Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. South Korea Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. India Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Australia Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Taiwan Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Indonesia Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Thailand Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Malaysia Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Philippines Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country (2018-2029)
    Figure 49. Latin America Neuroendocrine Tumor Drug Revenue Market Share by Country (2018-2029)
    Figure 50. Mexico Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 51. Brazil Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Argentina Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2018-2029)
    Figure 54. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2018-2029)
    Figure 55. Turkey Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 56. Saudi Arabia Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 57. UAE Neuroendocrine Tumor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 58. Global Sales Market Share of Neuroendocrine Tumor Drug by Type (2018-2029)
    Figure 59. Global Revenue Market Share of Neuroendocrine Tumor Drug by Type (2018-2029)
    Figure 60. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2018-2029)
    Figure 61. Global Sales Market Share of Neuroendocrine Tumor Drug by Application (2018-2029)
    Figure 62. Global Revenue Market Share of Neuroendocrine Tumor Drug by Application (2018-2029)
    Figure 63. Global Neuroendocrine Tumor Drug Price (USD/Pcs) by Application (2018-2029)
    Figure 64. Neuroendocrine Tumor Drug Value Chain
    Figure 65. Neuroendocrine Tumor Drug Production Process
    Figure 66. Channels of Distribution (Direct Vs Distribution)
    Figure 67. Distributors Profiles
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Eisai
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Frequently Asked Questions
Neuroendocrine Tumor Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neuroendocrine Tumor Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neuroendocrine Tumor Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports